Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Covid19

In brief

Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection

Key facts

Study ID

NCT04488575

Run by

Evelo Biosciences, Inc.

People needed

16

Starts

2020-08-26

Expected to finish

2021-05-19

Last updated by the study team

2022-12-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Robert Wood Johnson University Hospital — New Brunswick, New Jersey, United States
• The University Hospital — Newark, New Jersey, United States
• DHR Health Institute — Edinburg, Texas, United States
• Hacettepe University Adult Hospital — Ankara, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.